tetramethylpyrazine nitrone

Tetramethylpyrazine nitrone (TBN) is a synthetic small molecule derivative of tetramethylpyrazine (TMP), designed by adding a nitrone pharmacophore to the TMP structure. It acts as a multifunctional neuroprotectant and free radical scavenger with demonstrated efficacy in preclinical models of neurodegenerative diseases, muscular dystrophy, and renal disorders. Mechanistically, TBN exerts its effects through several pathways: - Scavenging reactive oxygen species (ROS) such as hydroxyl radicals, superoxide anions, and peroxynitrite. - Antagonizing L-type calcium channels to reduce calcium overload. - Modulating autophagy and mitochondrial function. - Reducing neuroinflammation. - Activating brain-derived neurotrophic factor signaling. - Stimulating cyclic AMP response element-binding protein (CREB). - Inhibiting mammalian target of rapamycin (mTOR) pathway activity. TBN has shown potential in reducing amyloid β deposition in Alzheimer's disease models by modulating APP expression and BACE1 activity[1][2]. It also improves motor deficits and muscle pathology in Duchenne muscular dystrophy animal models[3], protects against ischemic neuronal injury[5], regulates iron homeostasis via hypoxia-inducible factor activation for renal anemia[8], and is under clinical development for ischemic stroke, diabetic nephropathies, and amyotrophic lateral sclerosis[7].

Brand names

NitoxazineNitrazine

Other names

tetramethylpyrazine nitroneTBN